Dysglycemia and the Risk of Cardiovascular Events

Evidence-Based Cardiology: Third Edition

Volumn , Issue , 2010, Pages 179-189

  Gerstein, Hertzel C ^a   Punthakee, Zubin ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Diabetes mellitus common chronic condition defined on the basis of high glucose levels; Dysglycemia independent risk factor for CVD; Dysglycemia risk of cardiovascular events; Glucose metabolism promoting cellular damage; Glycation of variety of proteins promoting CVD; Hyperglycemia and CVD; Patients with CVD increased levels of proinsulin and split products

Indexed keywords

EID: 84887180107     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444309768.ch14     Document Type: Chapter

References (76)

1. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368 (9529): 29-36.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241 (19): 2035-8.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
4. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10059 male Israeli civil servants and municipal employees. A 23 year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology 1993; 82: 100-21.
5. Punthakee Z, Werstuck GH, Gerstein HC. Diabetes and cardiovascular disease: explaining the relationship. Rev Cardiovasc Med 2007; 8 (3): 145-53.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31 (suppl 1): S55-60.
7. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
8. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (suppl 1): S5-20.
9. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20 (7): 1183-97.
10. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24 (2): 137-44.
11. Wong TY, Liew G, Tapp RJ et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population -based cross-sectional studies. Lancet 2008; 371 (9614): 736-43.
12. Gerstein HC, Santaguida P, Raina P et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78 (3): 305-12.
13. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26 (11): 3160-7.
14. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28 (1): 88-136.
15. Secree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance: prevalence and projections. In: Allgot B, Gan D, King H et al, eds. Diabetes Atlas, 2nd edn. Brussels: International Diabetes Federation, 2003: 17-71.
16. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007; 369 (9563): 750-6.
17. Public Health Agency of Canada. Diabetes in Canada: Highlights from the National Diabetes Surveillance System 2004-2005. Ottawa: Public Health Agency of Canada, 2005.
18. Centers for Disease Control and Prevention. Prevalence of Diagnosed Diabetes by Age, United States, 1980-2005. Available at: www.cdc.gov/diabetes/statistics/prev/
19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30 (suppl 1): S42-7.
20. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332 (7533): 73-8.
21. Moss SE, Klein R, Klein BEK, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994; 154: 2473-9.
22. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12.
23. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005; 165 (16): 1910-16.
24. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141 (6): 421-31.
25. Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edelstein SL. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol 1991; 133 (6): 565-76.
26. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; 8183: 1373-6.
27. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycemia: the Whitehall study. BMJ Clin Res Ed 1983; 287 (6396): 867-70.
28. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006; 29 (1): 26-31.
29. DECODE Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26 (3): 688-96.
30. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular even. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22 (2): 233-40.
31. Lawes CM, Parag V, Bennett DA et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004; 27 (12): 2836-42.
32. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141 (6): 413-20.
33. Neaton JD, Wentworth D, MRFIT Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart diseas. Overall findings and differences by age for 316,099 white men. Arch Intern Med 1992; 152 (1): 56-64.
34. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998; 128 (7): 524-33.
35. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347 (9006): 949-50.
36. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003; 23 (suppl 2): S1-S152.
37. Yan SF, Yan SD, Herold K, Ramsamy R, Schmidt AM. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. Endocrinol Metab Clin North Am 2006; 35 (3): 511-24, viii.
38. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114 (6): 597-605.
39. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14 (10): 979-86.
40. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414 (6865): 813-20.
41. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54 (6): 1615-25.
42. Han I, Kudlow JE. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 1997; 17 (5): 2550-8.
43. Han I, Oh ES, Kudlow JE. Responsiveness of the state of O-linked N-acetylglucosamine modification of nuclear pore protein p62 to the extracellular glucose concentration. Biochem J 2000; 350 Pt 1: 109-14.
44. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108 (9): 13418.
45. Du XL, Edelstein D, Rossetti L et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97 (22): 12222-6.
46. Werstuck GH, Khan MI, Femia G et al. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes 2006; 55 (1): 93-101.
47. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52 (3): 581-7.
48. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes . Diabetes 2004; 53 (suppl 1): S119-S124.
49. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404 (6779): 787-90.
50. Stumvoll M, Tataranni PA, Stefan N, Vozarova B, Bogardus C. Glucose allostasis. Diabetes 2003; 52 (4): 903-9.
51. Fontbonne A, Charles MA, Thibult N et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15 year follow-up. Diabetologia 1991; 34 (5): 356-61.
52. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97 (10): 996-1001.
53. Bavenholm P, Proudler A, Tornvall P et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 1995; 92 (6): 1422-9.
54. Haffner SM, Mykkanen L, Valdez RA et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab 1994; 79 (6): 1806-10.
55. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrin Rev 2002; 23 (2): 201-29.
56. Dubois M, Kerr-Conte J, Gmyr V et al. Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration. Diabetologia 2004; 47 (3): 463-9.
57. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 2002; 7 (2): 149-59.
58. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003; 88 (3): 1082-8.
59. Das UN. Insulin: an endogenous cardioprotector. Curr Opin Crit Care 2003; 9 (5): 375-83.
60. Leonetti F, Iozzo P, Giaccari A, Buongiorno A, Tamburrano G, Andreani D. Absence of clinically overt atherosclerotic vascular disease and adverse changes in cardiovascular risk factors in 70 patients with insulinoma. J Endocrinol Invest 1993; 16 (11): 875-80.
61. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353 (25): 2643-53.
62. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53.
63. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24): 2560-72.
64. Abraira C, Duckworth W, McCarren M et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003; 17 (6): 314-22.
65. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 (24): 2545-59.
66. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279-89.
67. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
68. Dormandy J, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
69. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290 (4): 486-94.
70. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368 (9541): 1096-105.
71. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393-403.
72. Ratner R, Goldberg R, Haffner S et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28 (4): 888-94.
73. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49 (2): 289-97.
74. Dagenais GR, Gerstein HC, Holman R et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31 (5): 1007-14.
75. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155 (1): 26-32.
76. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.